This article has Open Peer Review reports available.
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
© Zaanan et al.; licensee BioMed Central Ltd. 2014
Received: 2 July 2013
Accepted: 9 June 2014
Published: 14 June 2014
FOLFOX second-line treatment seems to be a validated option for patients with pancreatic cancer (PC) progressing after gemcitabine chemotherapy. However, other therapeutics strategy has developed in first-line therapy, as the FIRGEM phase II study that evaluated gemcitabine alone versus FOLFIRI.3 alternating with gemcitabine every two months. The present study assessed the efficacy and safety of FOLFOX after failure of the first-line therapy used in the FIRGEM study.
In this prospective observational cohort study, we analysed all consecutive patients who received second-line chemotherapy with FOLFOX among 98 patients with metastatic PC included in the FIRGEM study. Progression-free survival (PFS) and overall survival (OS) were estimated from the start of second-line chemotherapy using the Kaplan-Meier method.
Among 46 patients who received second-line chemotherapy, 27 patients (male, 55%; median age, 61 years; performance status (PS) 0–1, 44%) were treated with FOLFOX after progression to first-line gemcitabine alone (n = 20) or FOLFIRI.3 alternating with gemcitabine (n = 7). Grade 3 toxicity was observed in 33% of patients (no grade 4 toxicity). At the end of follow-up, all patients had progressed and 25 had died. No objective response was observed, and disease control rate was 36%. Median PFS and OS were 1.7 and 4.3 months, respectively. In multivariate analysis, PS was the only independent prognostic factor. For patients PS 0–1 versus 2–3, median PFS was 3.0 versus 1.2 months (log rank, p = 0.002), and median OS was 5.9 versus 2.6 months (log rank, p = 0.001).
This study suggests that FOLFOX second-line therapy offered interesting efficacy results with an acceptable toxicity profile in metastatic PC patients with a good PS.
Pancreatic cancer (PC) accounts for approximately 2-3% of all malignant neoplasms worldwide, but is the fifth cause of cancer-related death in Western countries . At the time of diagnosis, about half of patients have metastatic disease, with a very poor prognosis and a median overall survival (OS) of about 6 months . Palliative chemotherapy is most often the only treatment option for this group of patients. Until recently, gemcitabine was considered as the standard therapy based on a randomised phase III trial showing a better clinical benefit and survival compared to 5-fluorouracil (5FU) chemotherapy . Since then, several randomised studies have been performed to improve the efficacy of first-line chemotherapy by combining gemcitabine with other cytotoxic or molecular targeted agents . No significant improvement in OS has been observed with any gemcitabine doublet, except for erlotinib, which provided a relatively low benefit . More recently, two randomised phase III trials comparing gemcitabine with FOLFIRINOX and gemcitabine with gemcitabine plus nab-paclitaxel in first-line chemotherapy have shown a significant improvement in objective response rate (ORR), progression-free survival (PFS) and OS in patients with metastatic PC [6, 7]. However, these treatments are indicated only for selected patients with good performance status (PS) because of a higher rate of severe toxicities than with gemcitabine alone.
After first-line chemotherapy failure, there is no standard second-line therapy. At this time, only one randomised phase III trial including forty-six patients who had become resistant to gemcitabine suggested that the combination of 5FU and oxaliplatin as second-line therapy is superior to best supportive care (BSC) .
Over several years, our team developed the FOLFIRI.3 regimen in first-line treatment of metastatic PC, with interesting results in a phase II study . Subsequently, we performed a randomised phase II trial, named FIRGEM, to evaluate gemcitabine alone versus FOLFIRI.3 alternating with gemcitabine every two months in patients with previously untreated metastatic PC . After 23 months of median follow-up, patients receiving sequential treatment had a higher PFS rate at 6 months (31% versus 49%) and 1 year (11% versus 23%), a higher ORR (11% versus 40%) and manageable toxicities . Based on these results, this sequential treatment strategy should be compared with FOLFIRINOX in a phase III trial.
In the present prospective “Association des gastroentérologues oncologues” (AGEO) study, we report the efficacy and tolerability of second-line FOLFOX chemotherapy in patients included in the FIRGEM trial with PC that progressed after first-line gemcitabine or sequential treatment.
This study was reviewed and approved by the Pitié-Salpêtrière Hospital Ethics Committee for all participing centres. In this prospective observational cohort study, we analysed all consecutive patients who received second-line chemotherapy by FOLFOX among patients with metastatic PC included from October 2007 and March 2011 in the FIRGEM trial . All patients had measurable disease. After disease progression under first-line chemotherapy with gemcitabine alone or FOLFIRI.3 alternating with gemcitabine, the second-line treatment and protocol were left to the investigator’s discretion. All patients were over 18 years of age and provided signed written informed consent. The study was registered with EudraCT (N° 2006-005703-34).
The FOLFOX regimen consists of oxaliplatin 85 mg/m2 in 2 hours infusion, folinic acid 400 mg/m2 in 2 hours infusion, followed by 5FU bolus 400 mg/m2, then by 5FU continuous infusion 2400 mg/m2 in 46 hours. The chemotherapy was administered every two weeks until the patients declined further doses or until disease progression or limiting toxicities.
Before each cycle of administration, a physical examination and laboratory tests were performed, in order to evaluate the ECOG PS status of the patient and treatment tolerability.
Tumor evaluation was performed every two months after the first day of treatment (or earlier in patients with suspected disease progression) and consisted of a physical examination, laboratory tests including determination of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19–9 (CA 19–9), and computed tomography (CT) scans. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria . Objective response rate was defined as the percentage of patients who had a complete or partial response. Toxicity was graded before each cycle of chemotherapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). For this study, the cutoff date of analysis was March 2012.
The statistical tests were performed with STATA V11 software (STATA Corp, College Station, TX). Progression-free survival was calculated from the date of second-line therapy initiation to the date of progression or death (all causes), whichever came first. Surviving patients without disease progression were censored at the last visit date. Overall survival was calculated from the date of second-line therapy initiation to death (all causes). Surviving patients were censored on the last follow-up date. Progression-free and overall survival curves were estimated by the Kaplan-Meier method and compared with the log-rank test. For univariate and multivariate analyses, Cox’s proportional hazards model was used to calculate hazard ratios (HR) with 95% confidence intervals (CI) for PFS and OS. All tests were two-sided and a p-value < 0.05 was considered to be statistically significant.
No. of patients
Median age [range], years
61.4 [47.6 - 74.1]
ECOG performance status score
First line chemotherapy
FOLFIRI.3 alternating with Gemcitabine
Pancreatic tumor location
Distant lymph nodes
No. of metastatic sites involved
Baseline CA 19–9 level
≤ 37 UI/ml*
> 37 UI/ml
No. of cycle
A total of 168 chemotherapy cycles were administered in FOLFOX second-line treatment (median, 4; range, 1–28).
No. of Patients (%)
Tumor response and survival
Tumor Response and Survival
No. of Patients (%)
Median progression free survival (months) [95% CI]
1.7 [1.0 - 2.5]
Median overall survival (months) [95% CI]
4.3 [2.2 - 5.9]
Median OS from the start of the second-line chemotherapy was 4.3 months (95% CI, 2.2 – 5.9 months) (Figure 1). The 6-month and 1-year OS rates were 25.9% (95% CI, 11.5 – 43.1%) and 18.5% (95% CI, 6.8 – 34.8%), respectively.
Median OS from the start of first-line therapy was 12.6 months (95% CI, 7.1 - 26.3 months) for patients treated with FOLFIRI.3 alternating with gemcitabine, and 8.5 months (95% CI, 6.9 – 10.6 months) for patients treated with gemcitabine alone.
In univariate analysis, we evaluated several factors potentially affecting PFS or OS in FOLFOX second-line chemotherapy (sex, age, ECOG PS, first-line chemotherapy protocol, PFS in first-line chemotherapy, number of metastatic sites and baseline CA 19–9 level). For PFS, we observed that ECOG PS [0–1 versus 2–3; HR = 4.00 (95% CI, 1.5 – 10.4), p < 0.01] and PFS in first-line chemotherapy [>6 versus ≤ 6 months; HR = 2.85 (95% CI, 1.0 - 7.9), p = 0.045] were significantly associated with longer PFS in second-line FOLFOX chemotherapy. For OS, we observed that only ECOG PS [0–1 versus 2–3; HR = 4.58 (95% CI, 1.7 – 12.1), p < 0.01] was significantly associated with longer OS in second-line FOLFOX chemotherapy. The first-line chemotherapy protocol used (gemcitabine alone versus FOLFIRI.3 alternating with gemcitabine) was not correlated with PFS or OS in second-line FOLFOX chemotherapy.
PC has been considered as chemo-refractory disease for a long time. Patients with metastatic PC that progresses after 5FU-based chemotherapy have had a little opportunity to receive second-line chemotherapy, mainly because of poor PS prohibiting further therapy. Gemcitabine first-line chemotherapy has been a major advance in the medical management of metastatic PC, allowing improvement of cancer-related symptoms, clinical benefit and a modest survival advantage. A significant percentage of patients whose PC progresses on gemcitabine chemotherapy still have a relatively good performance status and could benefit from a second-line therapy. Several studies including a relatively small number of patients have evaluated different anti-tumor drugs in this setting, mainly cisplatin , irinotecan [13, 14], taxanes  and raltitrexed . None of these drugs has yielded a significant survival benefit after gemcitabine-based first-line chemotherapy .
Oxaliplatin and fluoropyrimidine as second-line chemotherapy in advanced pancreatic cancer
No. of Patients
ECOG Performance status (PS)
Main Toxicities grade 3-4
Androulakis N et al., 2005 
oxali 180 mg/m2 q3weeks
PS 0, n=4 PS 1, n=9 PS 2, n=5
Diarrhoea 5% Vomiting 5% (Neutropenia 0%)
Tsavaris N et al., 2005 
oxali 50 mg/m2 D1,Leucovorin 50 mg/m2 D1,5FU 500 mg/m2 D1,q1 week
KPS 100-80%, n=10 KPS 70-50%, n=20
Leucopenia 16% Diarrhoea 14%
Mitry E et al., 2005 
Oxaliplatin, n=10 5FU, n=8
oxaliplatin 130 mg/m2 D1,5FU 1000 mg/m2 D1-D4,q3weeks
PS 0-1, n=4PS 2, n=7 PS > 2, n=4 Unknown, n=3
Neutropenia 19% Anemia 25% Asthenia 56%
Xiong HQ et al., 2008 
oxaliplatin 110–130 mg/m2 D1,capecitabine 1.5-2 g/m2 D1-D14q3week
PS 0, n=4 PS 1, n=16 PS 2, n=8
Asthenia 13% Diarrhoea 5%
Pelzer U et al., 2009 
oxaliplatin 85 mg/m2 D8, 22 folinic acid 500 mg/m2 D1,8,15,225FU 2600 mg/m2 D1,8,15,22 q6weeks
KPS 90-60%, n=37
Nausea/vomiting 11% Diarrhoea 12%
Novarino A et al., 2009 
Gem alone, n=13 Gem/5FU/cisplatin, n=5 Gem/5FU, n=4 Gem/oxaliplatin, n=1
oxaliplatin 40 mg/m2 D1,8,15 leucovorin 250 mg/m2 D1,8,15 5FU 500 mg/m2 D1,D8,15 q4weeks
PS 0, n=6 PS 1, n=11 PS 2, n=6
Diarrhoea 9% (Neutropenia 0%)
Yoo C et al., 2009 
Randomised phase II (versus FOLFIRI3)
Gem alone, n=2Gem/cap, n=26 Gem/erlotinib, n=2
oxaliplatin 85 mg/m2 D1 leucovorin 400 mg/m2 D1 5FU 2000 mg/m2 D1,D2 q2weeks
PS 0, n=5 PS 1, n=24 PS 2, n=1
Neutropenia 20% Asthenia 14%
Pelzer U et al., 2011 
Randomised phase III (versus BSC)
oxaliplatin 85 mg/m2 D8, 22 folinic acid 200 mg/m2 D1,8,15,22 5FU 2000 mg/m2 D1,8,15,22 q6weeks
KPS 100-90%, n=12 KPS 80-70%, n=11
4.82 mo (vs 2.3 mo BSC)
Diarrhoea 9% (Neutropenia 0%)
To our knowledge, only one phase III randomised study has compared 5FU with oxaliplatin (OFF regimen) versus BSC after tumor progression on first-line gemcitabine chemotherapy . Among the 46 patients out of 165 planned, those treated with OFF had a significantly longer median OS [4.82 months (95% CI, 4.29 – 5.35 months)] than patients who received BSC [2.30 months (95% CI, 1.76 – 2.83 months)] [HR = 0.45 (95% CI, 0.24 – 0.83), p = 0.008]. The median OS from the start of first-line gemcitabine therapy was 9.09 months (95% CI, 6.97 – 11.21 months) for the OFF group and 7.9 months (95% CI, 4.95 – 10.84 months) for the BSC group [HR = 0.50 (95% CI, 0.27 – 0.95), p = 0.031] . Although stopped prematurely because BSC alone was no longer accepted by participating centres, this phase III study provided for first time evidence of the survival benefit of second-line chemotherapy for patients with advanced PC.
In our study, the survival results of patients receiving FOLFOX as second-line chemotherapy seem to be in line with those published by Pelzer et al. . Toxicity was manageable without grade 4 side effects, and we noted no toxic death. As shown in other studies, we observed that ECOG PS was an independent prognostic factor . The median OS for PS 0–1 patients was 5.9 months compared with 2.6 months for PS 2–3 patients. As suggested by others studies, PFS in first-line therapy seemed to impact the PFS in second-line chemotherapy [16, 23, 24], though this result was not statistically significant in our multivariate analysis (p = 0.09).
Our study is the first to evaluate the FOLFOX regimen in second-line treatment after FOLFIRI.3 based-chemotherapy. However, these results should be interpreted with caution because of the relatively small number of patients included. Notably, we observed that only approximately 25% (7 of 27) of patients treated with second-line FOLFOX had received FOLFIRI.3 alternating with gemcitabine in first-line chemotherapy (Table 1). In this study, investigators preferentially proposed FOLFOX after gemcitabine failure, while gemcitabine-based treatment was preferred after failure of the sequential arm. Moreover, among patients who received the sequential arm in first-line, 7 were still being treated in first-line (compared with none in gemcitabine arm) at the cutoff date of analysis.
In recent years, two randomised phase III trials have shown that FOLFIRINOX or gemcitabine plus nab-paclitaxel improved survival compared with gemcitabine alone in patients with metastatic PC [6, 7]. However, these treatments are indicated only for selected patients because of a higher incidence of grade 3 or 4 toxicities. Moreover, limiting neurotoxicity of oxaliplatin or nab-paclitaxel could require therapy to be changed or stopped in patients who are still responding and have a good PS. The development of a strategy to limit toxicity could be interesting for treatment of metastatic PC patients. In the FIRGEM phase II trial, we evaluated FOLFIRI.3 alternating with gemcitabine in order to prevent the phenomena of cross-drug resistance and limiting toxicity inherent to any treatment . Furthermore, the FIRGEM strategy, which does not lead to neurotoxicity, allows patients to be given second-line treatment with FOLFOX.
This prospective study suggests that FOLFOX second-line therapy allows an interesting antitumor efficacy with a manageable toxicity profile in metastatic PC patients with a good PS who had been pretreated in the FIRGEM study. FOLFOX is a validated option in second-line therapy, which may be offered to patients who previously received first-line treatment without limiting neurotoxicity. The sequential FIRGEM first-line treatment followed by FOLFOX should be compared with FOLFIRINOX followed by gemcitabine in a phase III randomised study.
We thank the clinical research associates of the centres that participated in this study.
Financial support for this research was provided by AGEO (Association des gastroentérologues oncologues/Gastroenterologists Oncologists Association).
- Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010, 46 (4): 765-781. 10.1016/j.ejca.2009.12.014.View ArticlePubMedGoogle Scholar
- Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS: Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007, 110 (4): 738-744. 10.1002/cncr.22852.View ArticlePubMedGoogle Scholar
- Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997, 15 (6): 2403-2413.PubMedGoogle Scholar
- Trouilloud I, Dubreuil O, Boussaha T, Lepere C, Landi B, Zaanan A, Bachet JB, Taieb J: Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol. 2011, 35 (5): 364-374. 10.1016/j.clinre.2011.02.002.View ArticlePubMedGoogle Scholar
- Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007, 25 (15): 1960-1966. 10.1200/JCO.2006.07.9525.View ArticlePubMedGoogle Scholar
- Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364 (19): 1817-1825. 10.1056/NEJMoa1011923.View ArticlePubMedGoogle Scholar
- Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, Seay TE, Tjulandin S, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol. 2013, 30 (suppl 34; abstr LBA148): 2012-Google Scholar
- Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, Riess H, Oettle H: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011, 47 (11): 1676-1681. 10.1016/j.ejca.2011.04.011.View ArticlePubMedGoogle Scholar
- Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G, Desrame J: FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol. 2007, 18 (3): 498-503.View ArticlePubMedGoogle Scholar
- Trouilloud I, Dupont-Gossart AC AC, Artru P, Lecomte T, Gauthier M, Aparicio T, Thirot-Bidault A, Malka D, Bonnetain F, Taieb J: FIRGEM, a sequential FOLFIRI.3 (CPT11 plus folinic acid plus 5-FU) followed by Gemcitabine or Gemcitabine alone in patients with previously untreated metastatic pancreatic adenocarcinoma: results of a randomized multicenter AGEO phase II trial. Ann Oncol. 2012, abstract 710P,Google Scholar
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093/jnci/92.3.205.View ArticlePubMedGoogle Scholar
- Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010, 59 (11): 1527-1534. 10.1136/gut.2010.216135.View ArticlePubMedPubMed CentralGoogle Scholar
- Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, Valmadre G, Ferrara D, Veltri E, Codignola C, Labianca R: FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012, 69 (6): 1641-1645. 10.1007/s00280-012-1875-1.View ArticlePubMedGoogle Scholar
- Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL: A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009, 101 (10): 1658-1663. 10.1038/sj.bjc.6605374.View ArticlePubMedPubMed CentralGoogle Scholar
- Cereda S, Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother. 2008, 20 (4): 509-512. 10.1179/joc.2008.20.4.509.View ArticlePubMedGoogle Scholar
- Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006, 94 (6): 785-791. 10.1038/sj.bjc.6603026.View ArticlePubMedPubMed CentralGoogle Scholar
- Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P: Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004, 15 (3): 467-473. 10.1093/annonc/mdh098.View ArticlePubMedGoogle Scholar
- Androulakis N, Syrigos K, Polyzos A, Aravantinos G, Stathopoulos GP, Ziras N, Mallas K, Vamvakas L, Georgoulis V: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005, 23 (1): 9-12. 10.1081/CNV-46502.View ArticlePubMedGoogle Scholar
- Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P: Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma: results of a phase II trial. Gastroenterol Clin Biol. 2006, 30 (3): 357-363. 10.1016/S0399-8320(06)73188-8.View ArticlePubMedGoogle Scholar
- Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008, 113 (8): 2046-2052. 10.1002/cncr.23810.View ArticlePubMedGoogle Scholar
- Pelzer U, Stieler J, Roll L, Hilbig A, Dorken B, Riess H, Oettle H: Second-line therapy in refractory pancreatic cancer. results of a phase II study. Onkologie. 2009, 32 (3): 99-102. 10.1159/000197769.PubMedGoogle Scholar
- Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, Milanesi E, Bertetto O, Ciuffreda L: Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol. 2009, 32 (1): 44-48. 10.1097/COC.0b013e31817be5a9.View ArticlePubMedGoogle Scholar
- Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs. 2005, 23 (4): 369-375. 10.1007/s10637-005-1446-y.View ArticlePubMedGoogle Scholar
- Herrmann C, Abel U, Stremmel W, Jaeger D, Herrmann T: Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. Oncology. 2007, 73 (5–6): 335-339.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/441/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.